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ABSTRACT
Background: E-cigarette use has been shown to have short-term acute effects among active 
users but less is known of the acute passive effects, particularly among individuals with existing 
respiratory diseases.
Objective: To investigate local and systemic effects of short-term passive vape exposure among 
patients with mild or moderate chronic obstructive pulmonary disease (COPD).
Methods: In a double-blinded crossover study 16 non-smoking COPD-patients (mean age 68) 
were randomly exposed for 4 h to passive vape (median PM2.5: 18 µg/m
3 (range: 8–333)) and 
clean air (PM2.5 < 6 µg/m
3) separated by 14 days. Particles were measured using an ultrafine 
particle counter (P-TRAK) and a scanning mobility particle sizer (SMPS). Health effects including 
Surfactant Protein-A (SP-A) and albumin in exhaled air, spirometry, FeNO, and plasma proteins 
were evaluated before, right after, and 24 hours after exposure. Participants reported symptoms 
throughout exposure sessions. Data were analyzed using mixed models.
Results: SP-A in exhaled air was negatively affected by exposure to vape and several plasma 
proteins increased significantly. Throat irritation was more pronounced during passive vape 
exposure, while FVC and FEV1 decreased, however, not significantly.
Conclusions: SP-A in exhaled air and some plasma proteins were affected by passive vape in 
patients with COPD indicating inflammation, showing that passive vape exposure is potentially 
harmful.
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As e-cigarettes are by some parties considered a heal-
thier alternative to conventional cigarettes, they are 
promoted as an aid to decrease or quit tobacco smok-
ing [1]. However, their use as an effective smoking 
cessation device is questionable [2,3] and so is the 
idea that they are safe to use [4,5]. There is concern 
that e-cigarettes may have adverse long-term health 
effects and serve as a gateway product to cigarettes 
[6,7]. Several studies focusing on short-term health 
effects among e-cigarette users indicate that e-cigarettes 
are not harmless. Evidence show that e-cigarettes are 
affecting the cardiovascular as well as the respiratory 
system including respiratory symptoms such as cough, 
sore throat and dry mouth, reduced lung function, 
increase in impedance, increased oxidative stress bio-
markers, decrease in exhaled NO (FeNO), signs of 
possible vascular damage, and increased blood pressure 
and heart rate in users [4,8–11].
E-cigarettes produce an aerosol often referred to as 
‘vapor’ that is inhaled by the user. Unlike conventional 
cigarettes, e-cigarettes produce no secondary or side- 
stream emissions; therefore, passive exposure (i.e. 
exposure to air exhaled by vapers) consists only of 
what the user exhales. As the number of e-cigarette 
users is increasing, so is exposure to passive vape. 
Also, the use of e-cigarettes is often permitted in other-
wise smoke-free areas causing passive vape exposure 
for individuals present [12]. Passive vape exposure 
remain a concern as previous studies have demon-
strated that vape from e-cigarettes can contain toxic 
chemicals that are harmful to health [13]. A WHO- 
commissioned review found that while there are a 
limited number of studies in this area, it can be con-
cluded that e-cigarette aerosol is a new air 
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contamination source for particulate matter, which 
includes fine and ultrafine particles, as well as 1,2- 
propanediol, VOCs, heavy metals, and nicotine [14]. 
It is reasonable to assume that the increased concen-
trations of toxicants from passive vape over back-
ground levels poses an increased risk for the health of 
all bystanders [14] – and, bystanders with respiratory 
disease might be even more sensitive.
More research is needed to better understand poten-
tial health effects to passive bystanders, especially 
among vulnerable populations, including individuals 
with existing respiratory disease, known to be frail to 
environmental exposure [15]. Thus, the objective of the 
present study was to investigate acute local and sys-
temic effects of short-term passive exposure to vape 
from e-cigarettes among individuals with mild or mod-
erate Chronic Obstructive Lung Disease (COPD). The 
hypothesis was that passive vape exposure would lead 
to inflammation in lungs and blood.
Materials and methods
Details on recruitment, exposures, clinical testing, and 
statistical analyses are provided in supplemental online 
material.
Design
In a randomized double-blind, crossover trial partici-
pants were exposed to two exposure sessions (Figure 
1). Each session lasted 4 h; either air mixed with aero-
sol from e-cigarette users (median PM2.5: 18 µg/m3 
(range: 8–333)) or clean filtered air (PM2.5 < 6 µg/m3) 
at least two weeks apart in order to eliminate carry- 
over effects. The filtered clean air and e-cigarette vape 
sessions were identical except for the air quality.
Participants
Non-smoking patients with mild or moderate COPD 
were recruited. Patients had a known diagnosis of 
COPD determined by symptoms and spirometry 
using FEV1/FVC below lower limit of normal and 
MRC score≥2 and CAT (COPD Assessment Test) 
score≥10. If patients were on long-acting bronchodila-
tors and inhaled corticosteroids, it was converted to 
short-acting bronchodilators one week prior to partici-
pation. Before any exposure session, participants were 
required to be without signs of infections or airway 
symptoms for at least one week, and not to have taken 
any medicine during at least 48 hours. Additionally, 
participants were asked by a doctor whether they had 
been abstaining from smoking/vaping, which had to be 
affirmed. We aimed to include 30 participants accord-
ing to our power calculation.
Exposure
Exposure sessions took place in an exposure chamber, 
while exposure generation took place in an adjacent 
chamber. Three participants were exposed at a time. 
The aerosol was generated by two or three vapers who, 
in turn, vaped on e-cigarettes. The most popular brand 
of e-cigarettes in Denmark was examined; Joyetech 
eGo AIO (with a 2 ml tank, standard battery capacity 
of 1500 mAh and a standard Cubis BF coil (0.6 ohm)). 
We chose the two most commonly sold e-juices in 
Denmark at the time of the study; The included e- 
juices were pre-made ‘Tobacco’ and ‘Strawberry’ fla-
vour (70% propylene glycol/30% vegetable glycerine) 
from ‘InSano’ containing 6 mg of nicotine acquired in 
containers of 10 ml. All participants were exposed to 
both flavours in combination. A controlled flow of 
aerosol was transferred from the vaping chamber to 
the exposure chamber by a pipe connection using a 
negative pressure of 10 Pascal. During clean air ses-
sions, vapers were present in the vaping chamber; 
however, they did not use e-cigarettes. Instead, they 
were chewing gum (Nicotinell® Fruit) with 4 mg nico-
tine and fruit taste in order to mask the exposure. The 
specific vape exposure levels used in this study were 
chosen to obtain levels comparable with real-life 
scenarios.
Data collection
Particle size range (7–500 nm) as well as gravimetric 
measurements were determined using particle counters 
and filters. Prior to, right after, and 24 hours following 
exposure each participant underwent a series of health 
examinations including sampling of Particles in 
Exhaled Air (PExA), spirometry, Fraction of Exhaled 
Nitrogen Oxide (FeNO), and a blood sample. During 
each exposure session, a questionnaire assessing symp-
toms was completed prior to exposure, every 30 min 
during exposure, and at the end of the exposure 
session.
Statistics
Mixed models based on the univariate repeated mea-
surements ANOVA were performed, taking into 
account the different design variables corresponding 
to the crossover design [16]. Model 1 included a 
time-exposure interaction. If the interaction was non- 
significant, model 2 without interaction was per-
formed. Surfactant Protein-A (SP-A) and albumin in 
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exhaled air were the primary outcomes of interest. 
Secondary outcomes were spirometry, FeNO, plasma 
proteins, and self-reported symptoms.
Ethics
The Ethical Committee in Central Denmark Region 
approved the study protocol (ref.no. 1–10-72-273-16) 
and the project was conducted in accordance with The 
Declaration of Helsinki. Participants had received writ-
ten and oral information about the project and pro-
vided written consent prior to participation.
Results
Sixteen patients (6 female; 10 male) with moderate 
severe COPD and a mean age of 67.6 years participated 
(See Table 1).
Exposures
As shown in Figure 2(a), the peak number of parti-
cles on days with vape exposure was approximately 
in the size range of 30–40 nm. Another peak, 
Figure 1. CONSORT (consolidated standards of reporting trials) flow diagram: Number of participants from enrollment to analysis. 
Table 1. Participant characteristics for the study population.
Characteristic Measure
Participants, N (%) 16 (100.0)
Female, n (%) 6 (37.5)
Male, n (%) 10 (62.5)
Ex-smoker, n (%) 16 (100.0)
Age in years, mean (min-max) 67.6 (56–77)
Height (cm), mean (SD) 171.9 (9.03)
FEV1* (liter), mean (SD) 1.52 (0.57)
FEV1* (% predicted), mean (SD) 0.57 (0.23)
FVC* (liter), mean (SD) 2.47 (0.57)
FVC* (% predicted), mean (SD) 0.73 (0.19)
FEV1/FVC*, mean (SD) 0.64 (0.33)
Definition of abbreviations: FEV1 = Forced Expiratory Volume in the first 
second; FVC = forced vital capacity. * The reported FEV1 and FVC were 
measured at participant’s pre-examination, which was held before final 
inclusion in the trial. 
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although minor, was seen for larger particles (200– 
500 nm), which is coinciding with information from 
the vapers on the coil overheating. Hence, these 
particles could derive from combustion. The particle 
mass peaked when the particle size was around 300– 
500 nm. On exposure days with clean air particle 
concentrations were very low (see Figure 2(b) for 
average concentrations). Figure E1 in the online 
data supplement shows the individual measurements 







































Particle mobility diameter (nm) 
Figure 2(a). Average SMPS size distribution of particles and corresponding mass distributions during a) days with passive vape, b) 
days with clean air. Mean particle size distribution (orange curve (dN/dlogDp (particle number (#)/cm3))) and particle mass (green 
curve (dM/dlogDp (µg/m3))) ± SD. In Figure 2(a) colored symbols are an average of six measurement series, grey symbols from at 












































Particle mobility diameter (nm) 
Figure 2(b) (Continued). 
4 K. ROSENKILDE LAURSEN ET AL.
Formaldehyde, acetone, and acetaldehyde
Average concentrations of formaldehyde, acetaldehyde 
and acetone in the exposure chamber were similar 
between experiments with or without vaping (see 
Figure E2 in the online data supplement). 
Measurements in the adjacent room with vapers and 
at the outlet during one exposure session, showed 
higher concentrations of acetaldehyde (mean ± SD) 
(3.2 ± 0.2 μg m−3) and acetone (15.2 ± 1.2 μg m−3) in 
the air from the adjacent room than in the exposure 
chamber (2.0 ± 0.2 μg m−3 and 7.2 ± 0.2 μg m−3, 
respectively), while formaldehyde was observed at simi-
lar levels (3.3 ± 0.1 μg m−3 in adjacent room and 
4.1 ± 0.2 μg m−3 in exposure chamber). In addition, 
an analysis method for nicotine in particle filter sam-
ples was developed, but, unfortunately, the method was 




All participants performed PExA-samples, however, 
data are only analyzed for nine out of 16 participants 
as samples from seven participants were ‘below limit of 
detection’ (<40 ng). Among those nine participants 
having enough sample material, three participants con-
tributed with only one measure and one person only 
contributed to measures on one of the exposure days – 
therefore only five participants are included in the 
mixed effect analyses. There was a significant increase 
in percent of SP-A in PExA-samples 24 hours after 
exposure start compared to before exposure start 
(p = 0.021), also the time-exposure interaction was 
significant for percent SP-A (p = 0.029) showing a 
decrease after passive vape exposure taking into 
account the diurnal effect (Table 2). Percent of SP-A 
in the PExA-sample increased after exposure to passive 
vape (0.579 (95% CI −0.483; 1.641)), however insignif-
icant. Exposure to passive vape did not affect percent of 
Albumin in PExA-samples or the Albumin/SP-A ratio.
Spirometry
Minor, however, borderline-significant reductions in 
FEV1 and FVC were observed for passive vape com-
pared to clean air (−0.046 l and −0.071 l, respectively) 
(see Table 3).
FeNO
As seen from Table 3, exposure to passive vape did not 
significantly affect FeNO when compared to exposure 
to clean air (−1.60 (95% CI −5.14; 1.94)).
Blood plasma
The time-exposure interaction was significant for sev-
eral of the analyzed proteins (see Table 4), indicating 
that a differential change in the plasma occurred dur-
ing the two exposure sessions. Albumin (p = 0.006) and 
Acetoacetate (p = 0.014) were highly significant, while 
other markers – in particular cholesterol and lipopro-
teins – were less pronounced, however, still significant. 
Citrate, free cholesterol in very large HDL plus trigly-
cerides in medium HDL, in plasma were positively 
associated by exposure to vape alone, though the 
majority of the measured proteins did not show any 
variations related to exposure (model 2). Time also had 
a significant influence on several of the proteins indi-
cating diurnal or post-prandial variation (results not 
shown).
Symptoms from eyes, nose, and throat
Data on symptoms were registered by all participants 
every 30 minutes during the 4-h exposure sessions 
Table 2. Change in particles in exhaled air comparing passive 




SP-A % Model 1
Passive vape exposure 0.579 (−0.483;1.641) 0.271
Measured after exposure 0.166 (−0.901;1.232) 0.751
Measured 24 h after exposure 1.437 (0.242;2.632) 0.021
Passive vape x after exposure −0.097 (−1.590;1.397) 0.895
Passive vape x 24 h after exposure −1.775 (−3.350;-0.199) 0.029
Albumin % Model 2
Passive vape exposure −0.814 (−2.457;0.828) 0.316
Measured after exposure −1.961 (−3.795;-0.127) 0.037
Measured 24 h after exposure −0.787 (−2.795;1.220) 0.427
Albumin/SP-A Model 2
Passive vape exposure −0.165 (−1.322;0.991) 0.771
Measured after exposure −1.156 (−2.436;0.124) 0.075
Measured 24 h after exposure −1.361 (−2.768;0.045) 0.057
Definition of abbreviations: SP-A = Surfactant Protein-A. In model 1 for 
Albumin % and Albumin/SP-A, the interaction term was not significant, 
why there is no results shown. 
Table 3. Change in lung outcomes comparing passive vape 
exposure to clean air exposure (reference).
Model 2 n Coefficient 95% CI p-value
Spirometry
FEV1 16 −0.045 (−0.096;0.004) 0.073
FVC 16 −0.071 (−0.146;0.004) 0.065
FEV1/FVC 16 0.002 (−0.014;0.010) 0.683
FeNO 14 −1.599 (−5.137;1.939) 0.370
Definition of abbreviations: FEV1 = Forced Expiratory Volume in the first 
second (liter); FVC = Forced Vital Capacity (liter); FeNO: Fractional Exhaled 
Nitric Oxide (NO) (ppb). * Two participants were unable to perform the 
exhaled nitric oxide test at all time points. 
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including 0 min of exposure, resulting in nine time 
points. As seen from Figure 3, differences in partici-
pants’ symptoms were mild when comparing days with 
passive vape to days with clean air ranging from 6–20% 
of maximum on the scale. However, throat irritation 
was significantly higher on days with passive vape 
compared to days with clean air at time 180 and 
210 min, showing that throat irritation worsened over 
time on days with passive vape. There were no differ-
ences on eye and nose irritation when comparing pas-
sive vape to clean air, except for eye irritation that 
became significantly higher as time went by when 
exposed to passive vape.
Discussion
In the present study, we have shown that exposure to 
passive vape from e-cigarettes resulted in symptoms 
and systemic health effects among COPD-patients. 
We found that SP-A in exhaled air was affected by 
time and exposure to vape concentrations of median 
18 µg/m3 (range: 8–333) indicating a negative effect of 
passive vape on SP-A the morning after exposure. 
Furthermore, several plasma proteins increased signifi-
cantly indicating inflammation caused by vape expo-
sure. We found a borderline significant decline in lung 
function, but no effect on FeNO among the 16 COPD- 
patients exposed to passive vape.
Average concentrations of formaldehyde, acetalde-
hyde and acetone were similar between days with and 
without vaping, which is in contrast to previous studies 
where emission of carbonyl compounds from thermal 
degradation of e-liquid constituents has been observed 
[17–19]. In our study, the air exchange was high 
(2.1 ± 0.2), and it seems that levels of carbonyl com-
pounds were also affected by other factors than vaping, 
such as emission of carbonyl compounds from partici-
pants. This might explain why no particular difference 
in carbonyls between exposure days was seen [20]. We 
measured particles along their way from the small 
chamber through the pipe connection and into the 
large chamber using a P-TRAK. We found that we 
only lost very few particles during the transportation. 
However, the exposure was purposely mixed with clean 
inlet air and diluted when entering the large chamber.
Our results regarding SP-A in the lungs after passive 
vape exposure are novel. The significant time-exposure 
interaction showed a differential change in SP-A in 
exhaled particles during the two different exposure 
scenarios; a decrease was observed after passive vape 
exposure compared to clean air. One reason for the low 
24-h level might be depletion of SP-A due to inflam-
mation caused be the passive vape exposure. Similarly, 
a study by McKenzie et al. found decreasing SP-A 
levels after acute exposure to nanoparticles [21]. SP-A 
is a pivotal part of the respiratory immune system; it 
has the ability to opsonize or bind pathogens and other 
invading micro-organisms to enhance phagocytic 
removal from the airways [22]. It seems likely that 
SP-A decrease after acute exposure to particles, as 
they perish after fighting invading micro-organisms. 
The clinical implications of decreasing SP-A levels are 
Table 4. Significant change in plasma proteins comparing passive vape exposure to clean air exposure (ref.).
Model 1 Exposure x time 24 h. coefficient 95% CI p-value
Total cholesterol 0.326 (0.031;0.621) 0.031
Total esterified cholesterol 0.236 (0.0177;0.454) 0.035
Total free cholesterol 0.090 (0.011;0.169) 0.026
Acetoacetate 0.024 (0.005;0.043) 0.014
Beta-hydroxybutyrate (bOHbutyrate) 0.026 (0.002;0.050) 0.031
Albumin 0.006 (0.002;0.010) 0.006
Cholesteryl esters in small VLDL (S-VLDL-CE) 0.013 (0.001;0.026) 0.042
Conc. of very small VLDL particles (XS-VLDL-P) 2.30E-09 (4.13E-11;4.56E-09) 0.046
Total lipids in very small VLDL (XS-VLDL-L) 0.031 (0.000;0.061) 0.048
Conc. of large LDL particles (L-LDL-P) 1.51E-08 (4.09E-10;2.99E-08) 0.044
Total lipids in large LDL (L-LDL-L) 0.110 (0.002;0.218) 0.047
Phospholipids in large LDL (L-LDL-PL) 0.023 (0.001;0.046) 0.044
Cholesteryl esters in large LDL (L-LDL-CE) 0.063 (0.002;0.124) 0.044
Conc. of medium LDL particles (M-LDL-P) 1.35E-08 (6.36E-10;2.65E-08) 0.040
Total lipids in medium LDL (M-LDL-L) 0.069 (0.002;0.136) 0.042
Phospholipids in medium LDL (M-LDL-PL) 0.012 (0.001;0.024) 0.041
Conc. of small LDL particles (S-LDL-P) 1.49E-08 (1.17E-09;2.86E-08) 0.034
Total lipids in small LDL (S-LDL-L) 0.042 (0.002;0.082) 0.037
Phospholipids in small LDL (S-LDL-PL) 0.008 (0.000;0.016) 0.047
Model 2 Exposure coefficient 95% CI p-value
Citrate 0.005 (0.001;0.010) 0.041
Conc. of very large HDL particle (XL-HDL-PL) 0.011 (0.002;0.021) 0.021
L-VLDL-PL % −0.160 (−0.317;-0.002) 0.047
Triglycerides in medium HDL (M-HDL-TG) 0.002 (0.001;0.004) 0.026
Plasma proteins are measured as mmol/L except from XS-VLDL-P, L-LDL-P, M-LDL-P, S-LDL-P, and XL-HDL-PL, which are measured as mol/L. 
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unclear, however, it has been shown that low levels 
increase the risk of infections, e.g. virus infections 
[22]. Therefore, in COPD-patients depleted levels of 
SP-A might increase the risk of exacerbations. We 
also observed a minor, however insignificant, increase 
after vape exposure alone (not taking time into 
account). This might be because SP-A initially 
increases to protect the lungs from, e.g. inhaled parti-
cles [23], followed by a depletion after having fought 
the invading micro-organisms.
While SP-A and albumin in exhaled air were the 
only primary outcomes in our study, several secondary 
outcomes were analyzed, however, they have to be 
viewed upon as hypothesis generating. Our findings 
of borderline significant negative changes in FEV1 
and FVC following passive vape exposure is differing 
from other experimental studies. In a chamber study, 
Flouris and colleagues exposed 15 never-smokers to 
machine-generated e-cigarette aerosol for a single 
hour after which they measured lung function. Never- 
smokers also underwent a control session with no 
emissions and a passive tobacco cigarette session. The 
assessment of lung function demonstrated that a one- 
hour passive e-cigarette vaping session did not signifi-
cantly interfere with normal lung function, and the 
same result applied to active e-cigarette users [24]. A 
lack of change in lung function was also found in some 
of our previous exposure studies where we observed 
airway inflammation [25], indicating that lung function 
measurements may be less sensitive than other mea-
surements. However, COPD-patients might be more 
sensitive with regard to changes in lung function than 
healthy volunteers. An important consideration in the 
present study was participant’s discontinuation of cor-
ticosteroids seven days before exposure start possibly 
affecting the level of hyper-responsiveness in the lung. 
Increased responsiveness would render the participants 
more frail to passive vape, and we did see an indication 
of an effect. A possible explanation for the decline in 
lung function not reaching significance is low power, as 
we expected SD of 1.5 in our power calculation. 
Importantly, absence of significant short-term changes 
in spirometry does not mean that e-cigarettes are 
harmless [26].
In our study, we observed a minor, but insignificant, 
decrease in FeNO concentrations following exposure to 
passive vape. Tzortzi et al. examined the effects of 
passive exposure to e-cigarette emissions on respiratory 
mechanics in a crossover experimental study with 40 
young healthy non-smokers [27]. All participants 
Figure 3. Mean symptoms (95% CI) as % of max1 (y-axis) experienced over time (0 min to 240 min) during the two exposure 
scenarios: Eye irritation, throat irritation, and nose irritation. 
1 Symptoms were scored by placing a cross on a 130 mm open Visual Analogue Scale (VAS). The intensity of any discomfort was registered as the 
length in mm from the left of the scale to the marker. The scores were rated from 0 to 100% with highest number corresponding to highest 
discomfort. Discomfort was evaluated as changes over time (as percentage of max).  
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underwent a 30-min control session with no emissions 
and two experimental sessions (0.5 and 1.5 ohm expo-
sure). In their study, FeNO decreased significantly post 
exposure in the 0.5-ohm session indicating immediate 
alterations [27]. A decrease in nitric oxide (NO) is 
opposite to the findings in some air pollution studies, 
where NO production has been reported to increase 
with high levels of air pollution indicating airway 
inflammation [28,29], however, in accordance with 
studies on exposure to active and passive smoking of 
conventional cigarettes and active use of e-cigarettes 
[30–33]. A decrease in NO after exposure to passive 
vape could be explained by a negative feedback 
mechanism as the NO in vape downregulates NO 
synthases in the lungs through the nitric oxide it con-
tains – similar to the mechanism observed by conven-
tional cigarette smoking [27,34].
In the present study, we found increased levels of 
several plasma proteins, including albumin, acetoace-
tate, and citrate. Citrate is known for its activation 
potential for innate immune reactions and it plays a 
critical role in many normal physiological activities. 
Dysregulation can lead to several consequences such 
as impaired blood coagulability [35]. We found 
increased levels of free and esterified cholesterols, 
which are biomarkers associated with cardiovascular 
inflammation related to PM exposure [36].
We found no evident change in self-reported symp-
toms of eye and nose irritation, however, throat irritation 
was more pronounced on days with passive vape expo-
sure, although to a limited extent. To our knowledge, no 
previous exposure study on passive vape has examined 
self-reported symptoms, however, our results comple-
ment studies with other designs and/or other subgroups 
of the population. Dicpinigaitis and colleagues found in 
their exposure study among 30 healthy volunteers a sig-
nificant inhibition of cough reflex sensitivity after a single 
session of active e-cigarette use [37]. In a cross-sectional 
study among youths with asthma, Bayly and colleagues 
found that passive vape exposure was associated with 
higher odds of reporting an asthma attack, i.e. shortness 
of breath, chest tightness, cough, and/or wheezing in the 
past 12 months [38].
Strengths and limitations
The crossover design, the randomization, and double- 
blinding were the major strengths of the present study. 
In addition, we used an up-to-date exposure chamber 
in which all conditions other than the exposures were 
kept constant. Another strength was using human 
vapers, which gives a more realistic exposure than 
using a vaping machine, as the aerosol released to the 
surroundings are as in real-life with regard to compo-
sition of chemicals and particles exhaled from the user 
[39]. It is questionable whether smoking machines are 
able to replicate human vaping behavior, as the inhaled 
aerosol undergoes changes in the human lung that is 
assumed to be attributed to deposition and evapora-
tion, and it is therefore uncertain whether results from 
studies relying on smoking machines are trustworthy 
[4,39]. However, using real vapers resulted in variabil-
ity in the exposure, as the vapers did not use a stan-
dardized vape procedure, since they were only 
instructed to vape in shifts. From previous studies, we 
know that there is a large degree of variability in user 
exposure to these aerosol constituents across patterns 
of e-cigarette use among other things [40]. We feel that 
the blinding by using fruit gum as placebo worked well, 
however, we did not perform a systematic analyses on 
the effect of blinding.
Our study had limitations such as low power due to 
few participants, and furthermore, not all participants 
were able to complete all health examinations resulting 
in missing data. We found it difficult to recruit mildly 
to moderately affected COPD-patients, who were able 
to take the time to participate and at the same time 
cope with the discontinuation of corticosteroids even 
for a period of seven days. The activities of participants 
in the hours and days before the exposure sessions 
could not be standardized or completely controlled 
for and were likely to cause random effects. Low and 
varying levels of aerosol was another limitation in our 
study. The difference between median particle counts 
for exposure days with clean air and days with passive 
vape was not pronounced and neither were levels of 
formaldehyde, acetaldehyde or acetone. On two out of 
eight exposure days with passive vape, the level of 
particle counts were quite high as some very experi-
enced vapers were present in the small chamber inhal-
ing and exhaling forcefully. Previous studies show that 
composition of the aerosol that is generated depends 
on the ingredients of the e-liquid, the e-liquid levels 
left, the characteristics of the e-cigarette including the 
electrical characteristics of the heating element, and 
that production of harmful substances is influenced 
by both battery voltage output and temperature 
reached, which complicates research in this field [4,40].
Although nicotine-free liquids are available, the use 
of liquids containing nicotine is more common [41], 
why we chose e-liquids with 6 mg nicotine. This was 
the lowest amount possible, and one might expect 
worse health effects with higher nicotine levels [8]. 
The low amount of nicotine was chosen in order for 
the vapers not to become unwell during vaping for 
several hours.
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In summary, we believe that a true, but very mild 
effect of passive vape occurred in this study, although 
chance is an alternative explanation, and therefore 
interpretation should be made with caution. The find-
ings of this study do not necessarily pertain to the 
background population; however, they might be gen-
eralized to other people with chronic respiratory 
disease.
Conclusion
In conclusion, the results of this study indicate that 
passive vape is capable of exerting acute small inflam-
matory responses in lungs and blood as well as throat 
irritation. Despite the study being modest in its size 
with a narrow scope, it offers new findings on the 
potential harm of e-cigarettes. Although more research 
is required, it is clear that e-cigarette emissions are not 
merely harmless aerosol. In the future, we recommend 
more studies on passive vape exposure in sensitive 
subgroups, and studies of people chronically exposed 
to passive vaping, as such studies are virtually non- 
existent.
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